公开(公告)号：US12157737B2

公开(公告)日：2024-12-03

申请号：US18319585

申请日：2023-05-18

Applicant: NOVARTIS AG

Inventor： Mallesh Bushaboina ,  Xin Chen ,  Atwood Kim Cheung ,  Andrew James Culshaw ,  Timothy Brian Hurley ,  Nancy Labbe-Giguere ,  Wolfgang Miltz ,  David Orain ,  Tajesh Patel ,  Srinivasan Rajagopalan ,  Till Roehn ,  David Andrew Sandham ,  Gebhard Thoma ,  Ritesh Bhanudasji Tichkule ,  Rudolf Wälchli

IPC: A61K31/438 ,  A61K31/506 ,  A61K45/06 ,  C07D471/10 ,  C07D519/00

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20240199593A1

公开(公告)日：2024-06-20

申请号：US18426461

申请日：2024-01-30

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian XIE

IPC: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention provides a crystalline form of (S)-2-amino-3-(3-(4-((3-fluoro-5-(1H-pyrazol-5-yl)pyridin-2-yl)oxy)phenyl)-1H-pyrazol-1-yl)propan-1-ol, in its free form;

a method for manufacturing said crystalline form, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20220117949A1

公开(公告)日：2022-04-21

申请号：US17421747

申请日：2020-01-09

Applicant: NOVARTIS AG

Inventor： Christian Loesche ,  Carlos PENNO ,  Till Roehn ,  Grazyna Wieczorek

IPC: A61K31/4439 ,  A61K45/06 ,  A61K9/48 ,  A61P17/00 ,  A61P17/10

Abstract: The present disclosure relates to methods for treating Hidradenitis Suppurativa using a LTA4H inhibitor. Also disclosed herein are LTA4H inhibitors, for treating Hidradenitis Suppurativa patients, as well as medicaments, dosing regimens, pharmaceutical formulations, combinations, dosage forms, and kits for use in the disclosed uses and methods.

公开(公告)号：US11453651B2

公开(公告)日：2022-09-27

申请号：US15895224

申请日：2018-02-13

Applicant: NOVARTIS AG

Inventor： Birgit Bollbuck ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn

IPC: A61K31/41 ,  A61K31/415 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/428 ,  C07D231/12 ,  C07D271/10 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D257/04 ,  A61K45/06 ,  A61K31/4439

Abstract: The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel heteroaryl butanoic acid derivatives, methods of using said compounds in the treatment of various diseases and disorders, and processes for preparing the said novel compounds.

公开(公告)号：US11932630B2

公开(公告)日：2024-03-19

申请号：US17716423

申请日：2022-04-08

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian Xie

IPC: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof,




a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US11708366B2

公开(公告)日：2023-07-25

申请号：US17400458

申请日：2021-08-12

Applicant: Novartis AG

Inventor： Mallesh Bushaboina ,  Xin Chen ,  Atwood Kim Cheung ,  Andrew James Culshaw ,  Timothy Brian Hurley ,  Nancy Labbe-Giguere ,  Wolfgang Miltz ,  David Orain ,  Tajesh Patel ,  Srinivasan Rajagopalan ,  Till Roehn ,  David Andrew Sandham ,  Gebhard Thoma ,  Ritesh Bhanudasji Tichkule ,  Rudolf Wälchli

IPC: C07D471/10 ,  A61K31/438 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D471/10 ,  A61K45/06 ,  C07D519/00

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;




wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20220348566A1

公开(公告)日：2022-11-03

申请号：US17716423

申请日：2022-04-08

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian XIE

IPC: C07D413/10 ,  A61K45/06 ,  A61K31/4245 ,  A61K31/4439 ,  C07D413/14 ,  C07D471/04 ,  A61K31/436 ,  C07D401/14 ,  C07D401/12 ,  C07D257/04 ,  A61K31/41

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.